HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer
Authors: Watanabe, Kazunori Browse this author
Nakamura, Toru Browse this author →KAKEN DB
Kimura, Yasutoshi Browse this author
Motoya, Masayo Browse this author
Kojima, Shigeyuki Browse this author
Kuraya, Tomotaka Browse this author
Murakami, Takeshi Browse this author
Kaneko, Tsukasa Browse this author
Shinohara, Yoshihito Browse this author
Kitayama, Yosuke Browse this author
Fukuda, Keito Browse this author
Hatanaka, Kanako C. Browse this author
Mitsuhashi, Tomoko Browse this author
Pittella-Silva, Fabio Browse this author
Yamaguchi, Toshikazu Browse this author
Hirano, Satoshi Browse this author →KAKEN DB
Nakamura, Yusuke Browse this author
Low, Siew-Kee Browse this author
Keywords: cell-free DNA
circulating tumor DNA
liquid biopsy
pancreatic cancer
tumor-informed approach
neoadjuvant therapy
next-generation sequencing
cancer prognosis
Issue Date: Oct-2022
Publisher: MDPI
Journal Title: International Journal of Molecular Sciences
Volume: 23
Issue: 19
Start Page: 11521
Publisher DOI: 10.3390/ijms231911521
Abstract: Pancreatic cancer is one of the cancers with very poor prognosis; there is an urgent need to identify novel biomarkers to improve its clinical outcomes. Circulating tumor DNA (ctDNA) from liquid biopsy has arisen as a promising biomarker for cancer detection and surveillance. However, it is known that the ctDNA detection rate in resected pancreatic cancer is low compared with other types of cancer. In this study, we collected paired tumor and plasma samples from 145 pancreatic cancer patients. Plasma samples were collected from 71 patients of treatment-naive status and from 74 patients after neoadjuvant therapy (NAT). Genomic profiling of tumor DNA and plasma samples was conducted using targeted next-generation sequencing (NGS). Somatic mutations were detected in 85% (123/145) of tumors. ctDNA was detected in 39% (28/71) and 31% (23/74) of treatment-naive and after-NAT groups, respectively, without referring to the information of tumor profiles. With a tumor-informed approach (TIA), ctDNA detection rate improved to 56% (40/71) and 36% (27/74) in treatment-naive and after-NAT groups, respectively, with the detection rate significantly improved (p = 0.0165) among the treatment-naive group compared to the after-NAT group. Cases who had detectable plasma ctDNA concordant to the corresponding tumor showed significantly shorter recurrence-free survival (RFS) (p = 0.0010). We demonstrated that TIA improves ctDNA detection rate in pancreatic cancer, and that ctDNA could be a potential prognostic biomarker for recurrence risk prediction
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University